Unification of Efforts to Improve Global Access to Cancer Therapeutics: Report From the 2022/2023 Access to Essential Cancer Medicines Stakeholder Summit

Author:

Briercheck Edward1ORCID,Pyle Doug2,Adams Cary3,Atun Rifat4,Booth Christopher5ORCID,Dent Jennifer6,Garcia-Gonzalez Pat7ORCID,Ilbawi Andre8ORCID,Jazieh Abdul Rahman9ORCID,Kerr David10ORCID,Knaul Felicia11ORCID,Kobayashi Emily12,Lim Christopher13ORCID,Maza Maurizio13,Milner Danny3ORCID,Navarro Maria Fernanda14ORCID,O'Brien Meg15ORCID,Rodriguez-Galindo Carlos16ORCID,Sullivan Richard17ORCID,Torode Julie17ORCID,Vokes Everett18ORCID,Gralow Julie2ORCID

Affiliation:

1. Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA

2. American Society of Clinical Oncology, Alexandria, VA

3. Union for International Cancer Control, Geneva, Switzerland

4. Department of Global Health and Population, Harvard University, Boston, MA

5. Division of Cancer Care and Epidemiology, Queen's University, Kingston, Canada

6. BIO Ventures for Global Health, Seattle, WA

7. The Max Foundation, Seattle, WA

8. Cancer Programme, World Health Organization, Geneva, Switzerland

9. Cincinnati Cancer Advisors, Cincinnati, OH

10. Nuffield Department of Clinical Laboratory Sciences, Oxford University, Oxford, United Kingdom

11. Department of Public Health Sciences, University of Miami, Miami, FL

12. Clinton Health Access Initiative, Boston, MA

13. Pan-American Health Organization, Washington, DC

14. The City Cancer Challenge Foundation, Geneva, Switzerland

15. American Cancer Society, Atlanta, GA

16. Department of Global Pediatric Medicine, St Jude Children's Research Hospital, Memphis, TN

17. Institute of Cancer Policy, King's College London, London, United Kingdom

18. Department of Medicine, University of Chicago, Chicago, IL

Abstract

PURPOSE There is an urgent need to improve access to cancer therapy globally. Several independent initiatives have been undertaken to improve access to cancer medicines, and additional new initiatives are in development. Improved sharing of experiences and increased collaboration are needed to achieve substantial improvements in global access to essential oncology medicines. METHODS The inaugural Access to Essential Cancer Medicines Stakeholder Meeting was organized by ASCO and convened at the June 2022 ASCO Annual Meeting in Chicago, IL, with two subsequent meetings, Union for International Cancer Control World Cancer Congress held in Geneva, Switzerland, in October 2022 and at the ASCO Annual Meeting in June of 2023. Invited stakeholders included representatives from cancer institutes, physicians, researchers, professional societies, the pharmaceutical industry, patient advocacy organizations, funders, cancer organizations and foundations, policy makers, and regulatory bodies. The session was moderated by ASCO. Past efforts and current and upcoming initiatives were initially discussed (2022), updates on progress were provided (2023), and broad agreement on resulting action steps was achieved with participants. RESULTS Summit participants recognized that while much work was ongoing to enhance access to cancer therapeutics globally, communication and synergy across projects and organizations could be enhanced by providing a platform for collaboration and shared expertise. CONCLUSION The summit resulted in new cross-stakeholder insights and planned collaboration addressing barriers to accessing cancer medications. Specific actions and timelines for implementation and reporting were established.

Publisher

American Society of Clinical Oncology (ASCO)

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3